Relationship between PAF-acether and thromboxane A2 biosynthesis in endotoxin-induced intestinal damage in the rat

Prostaglandins
N K Boughton-SmithB J Whittle

Abstract

PAF-receptor antagonists are known to inhibit gastrointestinal damage induced by endotoxin. In the present study, the interaction between the biosynthesis of PAF and thromboxane (TX) A2, as putative mediators of the acute intestinal damage induced by endotoxin, has been investigated in the anaesthetised rat. Bolus intravenous administration of lipopolysaccharide from E. coli (5-50 mg/kg) induced dose-related jejunal damage, assessed using both macroscopic and histological techniques. This damage was accompanied by significant increases in the jejunal formation of PAF determined by bioassay, and of TXB2, determined by radioimmunoassay. Pretreatment with the structurally-unrelated thromboxane synthase inhibitors, 1-benzyl imidazole (10-50 mg/kg) or OKY 1581 (25 mg/kg) substantially reduced both jejunal damage and TXB2 formation, but did not inhibit PAF formation. Likewise, pretreatment with indomethacin (5 mg/kg) or BW 755C (50 mg/kg) reduced jejunal damage and TXB2 formation but did not affect PAF formation. Pretreatment (2h) with dexamethasone (4 mg/kg) reduced jejunal damage and the formation of both TXB2 and PAF. Intravenous infusion of PAF (100 ng/kg/min for 10 min) induced jejunal damage and significantly increased the form...Continue Reading

References

Oct 1, 1978·British Journal of Pharmacology·J R Fletcher, P W Ramwell
Jan 1, 1985·Journal of Cardiovascular Pharmacology·L S OlanoffP V Halushka
Jan 1, 1986·Intensive Care Medicine·H A BallP V Halushka
Mar 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F GuarnerS Moncada
Aug 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·B J WhittleS Moncada
Sep 1, 1987·British Journal of Pharmacology·B J WhittleJ L Wallace
Feb 1, 1985·Immunopharmacology·P IñarreaM Sánchez-Crespo
Feb 26, 1985·European Journal of Pharmacology·Z TerashitaS Sumida
May 15, 1983·Thrombosis Research·M Radomski, S Moncada
Jun 1, 1983·Prostaglandins, Leukotrienes, and Medicine·S Fukumoto, K Tanaka
Jan 21, 1983·European Journal of Pharmacology·P BessinJ Benveniste

Citations

Jan 1, 1992·Agents and Actions·N K Boughton-SmithB J Whittle
Dec 4, 1990·European Journal of Pharmacology·N K Boughton-SmithS Moncada
Jun 23, 1995·European Journal of Pharmacology·J L WallaceS N Elliott
Feb 26, 2000·European Journal of Clinical Investigation·A A VrijR W Stockbrügger
Dec 1, 1990·British Journal of Pharmacology·I R HutchesonN K Boughton-Smith
Nov 1, 1993·British Journal of Pharmacology·N K Boughton-SmithS Moncada
Jun 1, 1995·British Journal of Pharmacology·F LászlóS Moncada
Jan 1, 1992·Annals of the New York Academy of Sciences·B J WhittleS Moncada
Feb 27, 2008·Journal of Clinical Biochemistry and Nutrition·Yuji NaitoToshikazu Yoshikawa
Jul 12, 2014·The Journal of Surgical Research·Katharina Effenberger-NeidnichtHerbert de Groot
Jul 1, 1997·Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research·B SchröppelU B Brückner
Apr 6, 2004·Gastrointestinal Endoscopy Clinics of North America·Robynne Chutkan, Nabil Toubia
Apr 22, 2008·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·S SinghG N Qazi
May 1, 1993·JPEN. Journal of Parenteral and Enteral Nutrition·K Gardiner, A Barbul
Nov 1, 1993·JPEN. Journal of Parenteral and Enteral Nutrition·K Gardiner, A Barbul
Dec 18, 2001·Experimental Biology and Medicine·J L Wallace, L Ma

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Nodding Syndrome

Nodding Syndrome is a neurological and epileptiform disorder characterized by psychomotor, mental, and growth retardation. Discover the latest research on Nodding Syndrome here.

LRRK2 & Microtubules

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease (PD). LRRK2 mutations in PD have been shown to enhance its association with microtubules. Here is the latest research.